Cisplatin treatment itself sometimes induces the activation of NF-κB in ovarian cancer…
- User
Cisplatin treatment itself sometimes induces the activation of NF-κB in ovarian cancer cells
- Assistant
Cisplatin is a chemotherapy drug commonly used to treat ovarian cancer. Research indicates that cisplatin treatment can activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway in ovarian cancer cells. This activation may contribute to the development of resistance to cisplatin therapy. NF-κB is a transcription factor that regulates genes involved in cell survival, proliferation, and inflammation. When activated by cisplatin, NF-κB can promote the expression of anti-apoptotic genes, potentially reducing the effectiveness of the treatment. Understanding this mechanism is crucial for developing strategies to overcome cisplatin resistance in ovarian cancer therapy.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.